Description
Enlonstobart is an investigational medication currently being studied in clinical trials for colorectal cancer. It is being evaluated in combination with other standard treatments like liposomal irinotecan, 5-Fluorouracil (5-FU), Leucovorin (LV), and Bevacizumab. The goal of these trials is to see if adding Enlonstobart to these existing treatments improves outcomes for patients with metastatic colorectal cancer who have already received at least one prior therapy (second-line treatment). Researchers are also looking at how Enlonstobart might affect biomarkers in tumor tissue, stool, and blood to understand its effects better. The trials aim to determine the safety and effectiveness of this combination therapy compared to standard treatments without Enlonstobart.
Mechanism of Action
The specific mechanism of action for Enlonstobart is not fully detailed in the available trial information. It is being investigated as part of a combination therapy for metastatic colorectal cancer. The trials are exploring its potential role alongside other established chemotherapy and targeted therapy agents.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.